Notice NOT-DA-23-012 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-083 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-24-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support a national program of mentored advanced career development and training in research for junior faculty in pediatric critical care medicine and pediatric trauma surgery. Such a program is necessary to fuel the pipeline of well trained young investigators and advance research in these two clinically demanding fields.

Notice NOT-PM-23-001 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-002 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-016 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-010 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-009 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-041 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.

Notice NOT-AT-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-018 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-055 from the NIH Guide for Grants and Contracts

Notice NOT-EB-22-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-033 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, regulatory submission preparation.

Funding Opportunity PA-23-044 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.

Funding Opportunity RFA-CA-23-019 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than 10 multicenter validation studies.

Funding Opportunity RFA-CA-23-018 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to establish an Academic-Industrial Partnership Program to develop new and/or validate existing technologies, methods, and assays for the capture and quantification of tumor associated cells, DNA, RNA, or exosomes in body fluids of patients with early stage disease or those at high risk; as well as distinguishing cancer from benign disease; or aggressive from indolent cancers. The precompetitive alliances with industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.